Achieve Life Sciences, Inc. (ACHV)
NASDAQ · Manufacturing · In vitro & in vivo diagnostic substances
$7.54−$0.2900 (−3.70%) on the dayAs of the close; data may be delayed.
ACHV price, last 12 months
Key stats
- Previous close
- $7.83
- Open
- $7.90
- Day range
- $7.51 – $7.96
- 52-week range
- $2.62 – $8.64
- Volume
- 1.4M
- Avg volume (20 days)
- 1.7M
- Market cap
- $775.9M
Performance
1W−5.5%
1M−8.8%
3M+25.3%
6M+160.9%
YTD+51.7%
1Y+144.8%
vs S&P 500, 1Y+128.0 pts
Technicals and fundamentals
About Achieve Life Sciences, Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
- Sector
- Manufacturing
- Industry
- In vitro & in vivo diagnostic substances
- Listed on
- NASDAQ
- Market cap
- $775.9M